Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-04

AUTHORS

D Cella, B Escudier, B Rini, C Chen, H Bhattacharyya, J Tarazi, B Rosbrook, S Kim, R Motzer

ABSTRACT

BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Therapy (FACT) Kidney Cancer Symptom Index (FKSI) and the European Quality of Life self-report questionnaire (EQ-5D). METHODS: In all, 723 patients received axitinib (starting dose 5 mg twice daily (b.i.d.)) or sorafenib (400 mg b.i.d.). The FKSI-15, including the disease-related symptoms (FKSI-DRS) subscale, was administered on day 1 before dosing, every 4 weeks and at end of treatment (EOT)/withdrawal. Statistical methods included a mixed-effects repeated-measures model. RESULTS: At baseline, patients in both arms had relatively high mean FSKI-15 and FKSI-DRS scores, comparable to the general US population. Subsequent on-treatment overall mean scores were similar between axitinib and sorafenib, and there was no substantial decline during treatment. Scores substantially worsened at EOT, mainly due to disease progression. CONCLUSION: Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib. More... »

PAGES

1571

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2013.145

DOI

http://dx.doi.org/10.1038/bjc.2013.145

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045286767

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23579211


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Self Report", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Northwestern University", 
          "id": "https://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 N. St, Clair \u2013 19th Floor Chicago, IL 60611, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cella", 
        "givenName": "D", 
        "id": "sg:person.012000260477.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex 94805, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "B", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic", 
          "id": "https://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Solid Tumor Oncology, The Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rini", 
        "givenName": "B", 
        "id": "sg:person.01113325143.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Global Outcomes Research, Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "C", 
        "id": "sg:person.01336277612.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336277612.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Global Outcomes Research, Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhattacharyya", 
        "givenName": "H", 
        "id": "sg:person.01077206246.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077206246.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tarazi", 
        "givenName": "J", 
        "id": "sg:person.01222051212.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222051212.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosbrook", 
        "givenName": "B", 
        "id": "sg:person.0750542406.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750542406.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "S", 
        "id": "sg:person.0600257665.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600257665.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motzer", 
        "givenName": "R", 
        "id": "sg:person.01234500340.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2008.21.4809", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003290766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.coc.0000258732.80710.05", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004340534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.coc.0000258732.80710.05", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004340534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2009.07.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005282499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2007.12.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005961010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2011.156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008255824", 
          "https://doi.org/10.1038/nrclinonc.2011.156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1524-4733.2007.00183.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013407434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(07)70285-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014916629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djn319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015009768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25219", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017587632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.5511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017988502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.06.132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022235480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.21.7034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022707753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737140.4.6.1081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027568609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27688", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028329927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-0299", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030448516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/02841860802047395", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034812208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2004.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036273503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036833851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.11.7275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038524147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0652", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040763592"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.10.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042449068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-5-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047538979", 
          "https://doi.org/10.1186/1477-7525-5-34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077232179", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/acprof:oso/9780195152968.001.0001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1098761631"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-04", 
    "datePublishedReg": "2013-04-01", 
    "description": "BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Therapy (FACT) Kidney Cancer Symptom Index (FKSI) and the European Quality of Life self-report questionnaire (EQ-5D).\nMETHODS: In all, 723 patients received axitinib (starting dose 5 mg twice daily (b.i.d.)) or sorafenib (400 mg b.i.d.). The FKSI-15, including the disease-related symptoms (FKSI-DRS) subscale, was administered on day 1 before dosing, every 4 weeks and at end of treatment (EOT)/withdrawal. Statistical methods included a mixed-effects repeated-measures model.\nRESULTS: At baseline, patients in both arms had relatively high mean FSKI-15 and FKSI-DRS scores, comparable to the general US population. Subsequent on-treatment overall mean scores were similar between axitinib and sorafenib, and there was no substantial decline during treatment. Scores substantially worsened at EOT, mainly due to disease progression.\nCONCLUSION: Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2013.145", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "108"
      }
    ], 
    "name": "Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial", 
    "pagination": "1571", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d7b7ee3b210a1d91d57be9c470d82aa673b94754fc45c4013db52d3bdae3f310"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23579211"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2013.145"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045286767"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2013.145", 
      "https://app.dimensions.ai/details/publication/pub.1045286767"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000437.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2013145"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.145'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.145'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.145'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2013.145'


 

This table displays all metadata directly associated to this object as RDF triples.

312 TRIPLES      21 PREDICATES      79 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2013.145 schema:about N0273c12a5b5044d692eb0a5c186eb20e
2 N0d273c40cf8a4466b9772a9e7166564c
3 N35bdb6e1783541eeb35f8da44cdf12b3
4 N40741d4fbe514df0bab713ecdab02368
5 N41b5239e6f5a4b6f9176129e372227c7
6 N4515e5ea5f5b40b68fc65952872b38f2
7 N4964cc5a6f364c51904fa12c1fab0719
8 N5cd304d1e2f444ad9e294b5f1488c434
9 N5d866b32aa9a4c49b278dd0dfe92e784
10 N7b7234c3cc6c48a59bf6297cf6e09325
11 N87ce18662efb4e049e38d6722b97c010
12 N8f333c8854f8476aa3b9236f6b199a6a
13 Na3ea07f962dd4f70bbc7b575a6e9073a
14 Nbdca705fe71844658d8b108d13094a17
15 Nc2fa586cea7645ccb3509dd955efb1e6
16 Nd1dd03fca6704f779b9f95baa55c2d09
17 Ndded7afe0e0a452bb69b45029d2afc2b
18 Ne9dce80a04a64729b4ca99c90314d7ea
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Nc789dd2e0dd940d3888b552cfe95716f
22 schema:citation sg:pub.10.1038/nrclinonc.2011.156
23 sg:pub.10.1186/1477-7525-5-34
24 https://app.dimensions.ai/details/publication/pub.1077232179
25 https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m
26 https://doi.org/10.1002/cncr.25219
27 https://doi.org/10.1002/cncr.27688
28 https://doi.org/10.1016/j.ccr.2004.09.006
29 https://doi.org/10.1016/j.ctrv.2007.12.001
30 https://doi.org/10.1016/j.ctrv.2009.07.003
31 https://doi.org/10.1016/j.ejca.2011.10.028
32 https://doi.org/10.1016/s0140-6736(07)61904-7
33 https://doi.org/10.1016/s0140-6736(08)61039-9
34 https://doi.org/10.1016/s0140-6736(11)61613-9
35 https://doi.org/10.1016/s1470-2045(07)70285-1
36 https://doi.org/10.1056/nejmoa060655
37 https://doi.org/10.1056/nejmoa065044
38 https://doi.org/10.1056/nejmoa066838
39 https://doi.org/10.1080/02841860802047395
40 https://doi.org/10.1093/acprof:oso/9780195152968.001.0001
41 https://doi.org/10.1093/jnci/92.3.205
42 https://doi.org/10.1093/jnci/djn319
43 https://doi.org/10.1097/01.coc.0000258732.80710.05
44 https://doi.org/10.1111/j.1524-4733.2007.00183.x
45 https://doi.org/10.1158/1078-0432.ccr-08-0652
46 https://doi.org/10.1200/jco.2004.06.132
47 https://doi.org/10.1200/jco.2007.11.7275
48 https://doi.org/10.1200/jco.2008.19.5511
49 https://doi.org/10.1200/jco.2008.21.4809
50 https://doi.org/10.1200/jco.2008.21.7034
51 https://doi.org/10.1200/jco.2009.23.9764
52 https://doi.org/10.1586/14737140.4.6.1081
53 https://doi.org/10.1634/theoncologist.2010-0299
54 schema:datePublished 2013-04
55 schema:datePublishedReg 2013-04-01
56 schema:description BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Therapy (FACT) Kidney Cancer Symptom Index (FKSI) and the European Quality of Life self-report questionnaire (EQ-5D). METHODS: In all, 723 patients received axitinib (starting dose 5 mg twice daily (b.i.d.)) or sorafenib (400 mg b.i.d.). The FKSI-15, including the disease-related symptoms (FKSI-DRS) subscale, was administered on day 1 before dosing, every 4 weeks and at end of treatment (EOT)/withdrawal. Statistical methods included a mixed-effects repeated-measures model. RESULTS: At baseline, patients in both arms had relatively high mean FSKI-15 and FKSI-DRS scores, comparable to the general US population. Subsequent on-treatment overall mean scores were similar between axitinib and sorafenib, and there was no substantial decline during treatment. Scores substantially worsened at EOT, mainly due to disease progression. CONCLUSION: Patient-reported outcomes were comparable for second-line axitinib and sorafenib and were maintained at relatively high levels while on treatment, but worsened at EOT. As duration of treatment was longer with axitinib than sorafenib, time to worsening of symptoms can be delayed longer with axitinib.
57 schema:genre research_article
58 schema:inLanguage en
59 schema:isAccessibleForFree true
60 schema:isPartOf Ncab04f25bd7f4438ad8ec0708b2ce917
61 Ne2c20784993c414c9c858c0cb113bf89
62 sg:journal.1017082
63 schema:name Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
64 schema:pagination 1571
65 schema:productId N57907fd39e414429b87c7ccf7e51e584
66 N6fd251db0d7543be95a13cc23971d3ba
67 N9a86dc8f94f948eb9e353f063e7ad8c2
68 N9f3d48847460418695aacd242b35ad9e
69 Ncbf51775b90040c1bb109dada360bc52
70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045286767
71 https://doi.org/10.1038/bjc.2013.145
72 schema:sdDatePublished 2019-04-10T16:30
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher N85bfd6aa8f4c4c9ca2bec4b1fef2179e
75 schema:url https://www.nature.com/articles/bjc2013145
76 sgo:license sg:explorer/license/
77 sgo:sdDataset articles
78 rdf:type schema:ScholarlyArticle
79 N0273c12a5b5044d692eb0a5c186eb20e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Imidazoles
81 rdf:type schema:DefinedTerm
82 N0d273c40cf8a4466b9772a9e7166564c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Female
84 rdf:type schema:DefinedTerm
85 N231ac7cf756449e4a17dbe992a0b91dd rdf:first sg:person.0750542406.97
86 rdf:rest N9f2d18c10e654ac49b730498b3299f6e
87 N31d7043c63974437ae3ca804194c191c rdf:first sg:person.01113325143.17
88 rdf:rest N6c287826dda74188bb78ab4e083a82e7
89 N35bdb6e1783541eeb35f8da44cdf12b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Protein Kinase Inhibitors
91 rdf:type schema:DefinedTerm
92 N40741d4fbe514df0bab713ecdab02368 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Niacinamide
94 rdf:type schema:DefinedTerm
95 N41b5239e6f5a4b6f9176129e372227c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Middle Aged
97 rdf:type schema:DefinedTerm
98 N4515e5ea5f5b40b68fc65952872b38f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Kidney Neoplasms
100 rdf:type schema:DefinedTerm
101 N4654add622cb42dc813fd6710676b2e3 rdf:first sg:person.01077206246.03
102 rdf:rest Nc8a24980181b4a93a505d2975947d800
103 N4964cc5a6f364c51904fa12c1fab0719 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Male
105 rdf:type schema:DefinedTerm
106 N508dca50c4764d4aa1ee919dc8f1e766 schema:name Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA
107 rdf:type schema:Organization
108 N57907fd39e414429b87c7ccf7e51e584 schema:name nlm_unique_id
109 schema:value 0370635
110 rdf:type schema:PropertyValue
111 N5cd304d1e2f444ad9e294b5f1488c434 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Aged, 80 and over
113 rdf:type schema:DefinedTerm
114 N5d866b32aa9a4c49b278dd0dfe92e784 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Humans
116 rdf:type schema:DefinedTerm
117 N6c287826dda74188bb78ab4e083a82e7 rdf:first sg:person.01336277612.07
118 rdf:rest N4654add622cb42dc813fd6710676b2e3
119 N6fd251db0d7543be95a13cc23971d3ba schema:name doi
120 schema:value 10.1038/bjc.2013.145
121 rdf:type schema:PropertyValue
122 N733b25d2b084453a80e76a989f80dc8d schema:name Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA
123 rdf:type schema:Organization
124 N7b7234c3cc6c48a59bf6297cf6e09325 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Aged
126 rdf:type schema:DefinedTerm
127 N85bfd6aa8f4c4c9ca2bec4b1fef2179e schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N87ce18662efb4e049e38d6722b97c010 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Antineoplastic Agents
131 rdf:type schema:DefinedTerm
132 N8f333c8854f8476aa3b9236f6b199a6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Indazoles
134 rdf:type schema:DefinedTerm
135 N9a86dc8f94f948eb9e353f063e7ad8c2 schema:name pubmed_id
136 schema:value 23579211
137 rdf:type schema:PropertyValue
138 N9f2d18c10e654ac49b730498b3299f6e rdf:first sg:person.0600257665.44
139 rdf:rest Ne0ea13c9fd1c4001a73390ca5f95e96e
140 N9f3d48847460418695aacd242b35ad9e schema:name dimensions_id
141 schema:value pub.1045286767
142 rdf:type schema:PropertyValue
143 Na3ea07f962dd4f70bbc7b575a6e9073a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Treatment Outcome
145 rdf:type schema:DefinedTerm
146 Nbdca705fe71844658d8b108d13094a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Young Adult
148 rdf:type schema:DefinedTerm
149 Nbf49b8b6df384b2f9824c47903508262 schema:name Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA
150 rdf:type schema:Organization
151 Nc2fa586cea7645ccb3509dd955efb1e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Self Report
153 rdf:type schema:DefinedTerm
154 Nc789dd2e0dd940d3888b552cfe95716f rdf:first sg:person.012000260477.10
155 rdf:rest Nfc8eb147f8dc4017afb559efc8d784e2
156 Nc8a24980181b4a93a505d2975947d800 rdf:first sg:person.01222051212.97
157 rdf:rest N231ac7cf756449e4a17dbe992a0b91dd
158 Ncab04f25bd7f4438ad8ec0708b2ce917 schema:issueNumber 8
159 rdf:type schema:PublicationIssue
160 Ncbf51775b90040c1bb109dada360bc52 schema:name readcube_id
161 schema:value d7b7ee3b210a1d91d57be9c470d82aa673b94754fc45c4013db52d3bdae3f310
162 rdf:type schema:PropertyValue
163 Nd1dd03fca6704f779b9f95baa55c2d09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Carcinoma, Renal Cell
165 rdf:type schema:DefinedTerm
166 Ndded7afe0e0a452bb69b45029d2afc2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Phenylurea Compounds
168 rdf:type schema:DefinedTerm
169 Ne0ea13c9fd1c4001a73390ca5f95e96e rdf:first sg:person.01234500340.18
170 rdf:rest rdf:nil
171 Ne2c20784993c414c9c858c0cb113bf89 schema:volumeNumber 108
172 rdf:type schema:PublicationVolume
173 Ne9dce80a04a64729b4ca99c90314d7ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Adult
175 rdf:type schema:DefinedTerm
176 Nfc8eb147f8dc4017afb559efc8d784e2 rdf:first sg:person.01304252172.82
177 rdf:rest N31d7043c63974437ae3ca804194c191c
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
182 schema:name Clinical Sciences
183 rdf:type schema:DefinedTerm
184 sg:journal.1017082 schema:issn 0007-0920
185 1532-1827
186 schema:name British Journal of Cancer
187 rdf:type schema:Periodical
188 sg:person.01077206246.03 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
189 schema:familyName Bhattacharyya
190 schema:givenName H
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077206246.03
192 rdf:type schema:Person
193 sg:person.01113325143.17 schema:affiliation https://www.grid.ac/institutes/grid.239578.2
194 schema:familyName Rini
195 schema:givenName B
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
197 rdf:type schema:Person
198 sg:person.012000260477.10 schema:affiliation https://www.grid.ac/institutes/grid.16753.36
199 schema:familyName Cella
200 schema:givenName D
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10
202 rdf:type schema:Person
203 sg:person.01222051212.97 schema:affiliation N508dca50c4764d4aa1ee919dc8f1e766
204 schema:familyName Tarazi
205 schema:givenName J
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222051212.97
207 rdf:type schema:Person
208 sg:person.01234500340.18 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
209 schema:familyName Motzer
210 schema:givenName R
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
212 rdf:type schema:Person
213 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
214 schema:familyName Escudier
215 schema:givenName B
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
217 rdf:type schema:Person
218 sg:person.01336277612.07 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
219 schema:familyName Chen
220 schema:givenName C
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336277612.07
222 rdf:type schema:Person
223 sg:person.0600257665.44 schema:affiliation N733b25d2b084453a80e76a989f80dc8d
224 schema:familyName Kim
225 schema:givenName S
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600257665.44
227 rdf:type schema:Person
228 sg:person.0750542406.97 schema:affiliation Nbf49b8b6df384b2f9824c47903508262
229 schema:familyName Rosbrook
230 schema:givenName B
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750542406.97
232 rdf:type schema:Person
233 sg:pub.10.1038/nrclinonc.2011.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008255824
234 https://doi.org/10.1038/nrclinonc.2011.156
235 rdf:type schema:CreativeWork
236 sg:pub.10.1186/1477-7525-5-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047538979
237 https://doi.org/10.1186/1477-7525-5-34
238 rdf:type schema:CreativeWork
239 https://app.dimensions.ai/details/publication/pub.1077232179 schema:CreativeWork
240 https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m schema:sameAs https://app.dimensions.ai/details/publication/pub.1036833851
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1002/cncr.25219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017587632
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1002/cncr.27688 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028329927
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/j.ccr.2004.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036273503
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1016/j.ctrv.2007.12.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005961010
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/j.ctrv.2009.07.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005282499
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/j.ejca.2011.10.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042449068
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1016/s1470-2045(07)70285-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014916629
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1080/02841860802047395 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034812208
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1093/acprof:oso/9780195152968.001.0001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1098761631
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1093/jnci/djn319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015009768
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1097/01.coc.0000258732.80710.05 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004340534
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1111/j.1524-4733.2007.00183.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013407434
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1158/1078-0432.ccr-08-0652 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040763592
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1200/jco.2004.06.132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022235480
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1200/jco.2007.11.7275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038524147
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2008.19.5511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017988502
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1200/jco.2008.21.4809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003290766
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1200/jco.2008.21.7034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022707753
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1586/14737140.4.6.1081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027568609
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1634/theoncologist.2010-0299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030448516
297 rdf:type schema:CreativeWork
298 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
299 schema:name Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex 94805, France
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.16753.36 schema:alternateName Northwestern University
302 schema:name Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 N. St, Clair – 19th Floor Chicago, IL 60611, USA
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.239578.2 schema:alternateName Cleveland Clinic
305 schema:name Solid Tumor Oncology, The Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
308 schema:name Global Outcomes Research, Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
309 rdf:type schema:Organization
310 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
311 schema:name Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
312 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...